Barclays’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $926K | Sell |
10,652
-120,784
| -92% | -$11.7M | ﹤0.01% | 2805 |
|
|
2025
Q4 | $14.1M | Sell |
131,436
-10,949
| -8% | -$1.16M | ﹤0.01% | 1449 |
|
|
2025
Q3 | $14.4M | Sell |
142,385
-208,813
| -59% | -$19.4M | ﹤0.01% | 1413 |
|
|
2025
Q2 | $22.2M | Buy |
351,198
+249,981
| +247% | +$15.3M | 0.01% | 1074 |
|
|
2025
Q1 | $5.36M | Sell |
101,217
-34,180
| -25% | -$1.9M | ﹤0.01% | 1859 |
|
|
2024
Q4 | $7.58M | Buy |
135,397
+29,000
| +27% | +$1.6M | ﹤0.01% | 1794 |
|
|
2024
Q3 | $5.57M | Buy |
106,397
+52,766
| +98% | +$2.53M | ﹤0.01% | 1997 |
|
|
2024
Q2 | $2.2M | Sell |
53,631
-73,905
| -58% | -$2.95M | ﹤0.01% | 2066 |
|
|
2024
Q1 | $5.53M | Sell |
127,536
-123,879
| -49% | -$5.42M | ﹤0.01% | 1784 |
|
|
2023
Q4 | $11.6M | Buy |
251,415
+10,154
| +4% | +$320K | ﹤0.01% | 1414 |
|
|
2023
Q3 | $5.53M | Buy |
241,261
+111,033
| +85% | +$2.49M | ﹤0.01% | 1270 |
|
|
2023
Q2 | $2.15M | Buy |
130,228
+43,110
| +49% | +$778K | ﹤0.01% | 1847 |
|
|
2023
Q1 | $1.55M | Sell |
87,118
-95,481
| -52% | -$2.4M | ﹤0.01% | 2390 |
|
|
2022
Q4 | $5.32M | Buy |
182,599
+18,246
| +11% | +$469K | ﹤0.01% | 1577 |
|
|
2022
Q3 | $4.03M | Buy |
164,353
+155,063
| +1,669% | +$2.88M | ﹤0.01% | 1294 |
|
|
2022
Q2 | $39K | Sell |
9,290
-11,909
| -56% | -$65.2K | ﹤0.01% | 4139 |
|
|
2022
Q1 | $245K | Sell |
21,199
-32,270
| -60% | -$283K | ﹤0.01% | 3296 |
|
|
2021
Q4 | $533K | Buy |
53,469
+18,175
| +51% | +$204K | ﹤0.01% | 3176 |
|
|
2021
Q3 | $461K | Buy |
35,294
+16,806
| +91% | +$257K | ﹤0.01% | 3230 |
|
|
2021
Q2 | $363K | Sell |
18,488
-55,795
| -75% | -$1.16M | ﹤0.01% | 3259 |
|
|
2021
Q1 | $1.58M | Buy |
74,283
+39,527
| +114% | +$1.15M | ﹤0.01% | 2479 |
|
|
2020
Q4 | $1.03M | Sell |
34,756
-62,369
| -64% | -$1.59M | ﹤0.01% | 2735 |
|
|
2020
Q3 | $2.1M | Sell |
97,125
-4,726
| -5% | -$108K | ﹤0.01% | 2051 |
|
|
2020
Q2 | $2.27M | Buy |
101,851
+8,127
| +9% | +$158K | ﹤0.01% | 2007 |
|
|
2020
Q1 | $1.43M | Sell |
93,724
-34,123
| -27% | -$611K | ﹤0.01% | 2602 |
|
|
2019
Q4 | $2.94M | Buy |
127,847
+113,881
| +815% | +$2.53M | ﹤0.01% | 2594 |
|
|
2019
Q3 | $302K | Sell |
13,966
-4,521
| -24% | -$97K | ﹤0.01% | 4658 |
|
|
2019
Q2 | $406K | Sell |
18,487
-1,036
| -5% | -$26.2K | ﹤0.01% | 4513 |
|
|
2019
Q1 | $536K | Buy |
19,523
+16,197
| +487% | +$465K | ﹤0.01% | 4043 |
|
|
2018
Q4 | $90K | Sell |
3,326
-3,301
| -50% | -$91.2K | ﹤0.01% | 5113 |
|
|
2018
Q3 | $193K | Buy |
6,627
+5,302
| +400% | +$168K | ﹤0.01% | 5035 |
|
|
2018
Q2 | $41K | Sell |
1,325
-2,843
| -68% | -$77.7K | ﹤0.01% | 5760 |
|
|
2018
Q1 | $84K | Buy |
4,168
+2,862
| +219% | +$76K | ﹤0.01% | 5508 |
|
|
2017
Q4 | $38K | Buy |
+1,306
| New | +$34.5K | ﹤0.01% | 5914 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Barclays's RYTM Position: Q1 2026 in Review
Barclays reduced its Rhythm Pharmaceuticals (RYTM) stake by 92% in Q1 2026, selling an estimated $11.7M and leaving 10,652 shares worth $926K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.
Barclays first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $22.2M in Q2 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Barclays held 10,652 shares of Rhythm Pharmaceuticals worth $926K as of Q1 2026.
- Barclays sold 120,784 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $11.7M.
- Rhythm Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2805 holding.
- Barclays first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Barclays's Rhythm Pharmaceuticals position peaked at $22.2M in Q2 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.